Singapore markets open in 3 hours 22 minutes
  • Straits Times Index

    3,111.65
    +18.85 (+0.61%)
     
  • S&P 500

    3,911.74
    +116.01 (+3.06%)
     
  • Dow

    31,500.68
    +823.28 (+2.68%)
     
  • Nasdaq

    11,607.62
    +375.42 (+3.34%)
     
  • BTC-USD

    21,330.08
    -70.79 (-0.33%)
     
  • CMC Crypto 200

    462.12
    +8.22 (+1.81%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Gold

    1,828.10
    -2.20 (-0.12%)
     
  • Crude Oil

    107.06
    -0.56 (-0.52%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Nikkei

    26,491.97
    +320.77 (+1.23%)
     
  • Hang Seng

    21,719.06
    +445.16 (+2.09%)
     
  • FTSE Bursa Malaysia

    1,436.70
    +5.65 (+0.39%)
     
  • Jakarta Composite Index

    7,042.94
    +44.67 (+0.64%)
     
  • PSE Index

    6,217.56
    +152.33 (+2.51%)
     

Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·10-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

– The SKYSCRAPER-01 study evaluating tiragolumab plus Tecentriq did not meet its co-primary endpoint of progression-free survival –

– The other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysis –

– The tiragolumab development program continues as planned in non-small cell lung cancer and other cancer types –

SOUTH SAN FRANCISCO, Calif., May 11, 2022--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from its Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone as an initial (first-line) treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer (NSCLC). The study did not meet its co-primary endpoint of progression-free survival. At this first analysis, the other co-primary endpoint of overall survival (OS) was immature, and the study will continue until the next planned analysis. A numerical improvement was observed in both co-primary endpoints. Data suggest that tiragolumab plus Tecentriq was well-tolerated and no new safety signals were identified when adding tiragolumab. Further analyses of these results are ongoing and data will be presented at an upcoming medical meeting.

"While these results are not what we hoped for in our first analysis, we look forward to seeing mature overall survival for this study to determine next steps," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. "We continue to believe that TIGIT may have a role in cancer treatment and we will share additional results from our tiragolumab program as they emerge."

The tiragolumab program continues to explore advances in multiple clinical trials, building on Tecentriq, with the goal of providing new treatment options in advanced and difficult-to-treat cancers as well as expanding into earlier stages of disease.

About the SKYSCRAPER-01 study

SKYSCRAPER-01 is a global Phase III, randomized double-blinded study evaluating tiragolumab plus Tecentriq® (atezolizumab) versus Tecentriq alone in 534 patients with first-line PD-L1-high locally advanced, unresectable or metastatic non-small cell lung cancer. Patients were randomized 1:1 to receive either tiragolumab plus Tecentriq or placebo plus Tecentriq, until disease progression, loss of clinical benefit or unacceptable toxicity. Co-primary endpoints are overall survival and progression-free survival.

About tiragolumab

Tiragolumab is an investigational novel immune checkpoint inhibitor with an intact Fc region. Tiragolumab selectively binds to TIGIT, a novel inhibitory immune checkpoint, which suppresses the immune response to cancer. Based on preclinical research, tiragolumab is thought to work as an immune amplifier with other cancer immunotherapies such as Tecentriq® (atezolizumab). The TIGIT pathway is distinct, but complementary to the PD-L1/PD-1 pathway. Dual blockade with tiragolumab and Tecentriq may help overcome immune suppression and restore the immune response.

About Tecentriq® (atezolizumab)

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

Tecentriq U.S. Indications

Tecentriq is a prescription medicine used to treat adults with:

A type of lung cancer called non-small cell lung cancer (NSCLC).

  • Tecentriq may be used alone as a treatment for their lung cancer:

    • to help prevent their lung cancer from coming back after their tumor(s) has been removed by surgery and they have received platinum-based chemotherapy, and

    • they have stage 2 to 3A NSCLC (patients should talk to their healthcare provider about what these stages mean), and

    • their cancer tests positive for "PD-L1".

  • Tecentriq may be used alone as their first treatment when their lung cancer:

    • has spread or grown, and

    • their cancer tests positive for "high PD-L1", and

    • their tumor does not have an abnormal "EGFR" or "ALK" gene

  • Tecentriq may be used with the medicines bevacizumab, paclitaxel, and carboplatin as their first treatment when their lung cancer:

    • has spread or grown, and

    • is a type called "non-squamous NSCLC," and

    • their tumor does not have an abnormal "EGFR" or "ALK" gene

  • Tecentriq may be used with the medicines paclitaxel protein-bound and carboplatin as their first treatment when their lung cancer:

    • has spread or grown, and

    • is a type called "non-squamous NSCLC," and

    • their tumor does not have an abnormal "EGFR" or "ALK" gene

  • Tecentriq may also be used when their lung cancer:

    • has spread or grown, and

    • they have tried chemotherapy that contains platinum, and it did not work or is no longer working

    • if their tumor has an abnormal "EGFR" or "ALK" gene, they should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working

It is not known if Tecentriq is safe and effective in children.

Important Safety Information

What is the most important information about Tecentriq?

Tecentriq can cause the immune system to attack normal organs and tissues in any area of the body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. Patients can have more than one of these problems at the same time. These problems may happen anytime during their treatment or even after their treatment has ended.

Patients should call or see their healthcare provider right away if they develop any new or worse signs or symptoms, including:

Lung problems

  • cough

  • shortness of breath

  • chest pain

Intestinal problems

  • diarrhea (loose stools) or more frequent bowel movements than usual

  • stools that are black, tarry, sticky, or have blood or mucus

  • severe stomach-area (abdomen) pain or tenderness

Liver problems

  • yellowing of the skin or the whites of the eyes

  • severe nausea or vomiting

  • pain on the right side of their stomach area (abdomen)

  • dark urine (tea colored)

  • bleeding or bruising more easily than normal

Hormone gland problems

  • headaches that will not go away or unusual headaches

  • eye sensitivity to light

  • eye problems

  • rapid heartbeat

  • increased sweating

  • extreme tiredness

  • weight gain or weight loss

  • feeling more hungry or thirsty than usual

  • urinating more often than usual

  • hair loss

  • feeling cold

  • constipation

  • their voice gets deeper

  • dizziness or fainting

  • changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems

  • decrease in their amount of urine

  • blood in their urine

  • swelling of their ankles

  • loss of appetite

Skin problems

  • rash

  • itching

  • skin blistering or peeling

  • painful sores or ulcers in mouth or nose, throat, or genital area

  • fever or flu-like symptoms

  • swollen lymph nodes

Problems can also happen in other organs.

These are not all of the signs and symptoms of immune system problems that can happen with Tecentriq. Patients should call or see their healthcare provider right away for any new or worse signs or symptoms, including:

  • Chest pain, irregular heartbeat, shortness of breath, or swelling of ankles

  • Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs

  • Double vision, blurry vision, sensitivity to light, eye pain, changes in eyesight

  • Persistent or severe muscle pain or weakness, muscle cramps

  • Low red blood cells, bruising

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

  • chills or shaking

  • itching or rash

  • flushing

  • shortness of breath or wheezing

  • dizziness

  • feeling like passing out

  • fever

  • back or neck pain

Complications, including graft-versus-host disease (GVHD), in people who have received a bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be serious and can lead to death. These complications may happen if patients undergo transplantation either before or after being treated with Tecentriq. A healthcare provider will monitor for these complications.

Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider will check patients for these problems during their treatment with Tecentriq. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may also need to delay or completely stop treatment with Tecentriq if patients have severe side effects.

Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:

  • have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus

  • have received an organ transplant

  • have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)

  • have received radiation treatment to their chest area

  • have a condition that affects their nervous system, such as myasthenia gravis or Guillain-Barré syndrome

  • are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant:

    • A healthcare provider should do a pregnancy test before they start treatment with Tecentriq

    • They should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq

  • are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into the breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

  • feeling tired or weak

  • decreased appetite

  • nausea

  • cough

  • shortness of breath

The most common side effects of Tecentriq when used in lung cancer with other anti-cancer medicines include:

  • feeling tired or weak

  • nausea

  • hair loss

  • constipation

  • diarrhea

  • decreased appetite

Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.

These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information about the benefits and side effects of Tecentriq.

Report side effects to the FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

Report side effects to Genentech at 1-888-835-2555.

Please see http://www.Tecentriq.com for full Prescribing Information and additional Important Safety Information.

About Genentech in cancer immunotherapy

Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus. With more than 20 immunotherapy molecules in development, Genentech is investigating the potential benefits of immunotherapy alone, and in combination with various chemotherapies, targeted therapies and other immunotherapies with the goal of providing each person with a treatment tailored to harness their own unique immune system.

In addition to Genentech’s approved PD-L1 checkpoint inhibitor, the company’s broad cancer immunotherapy pipeline includes other checkpoint inhibitors, individualized neoantigen therapies and T cell bispecific antibodies. For more information visit http://www.gene.com/cancer-immunotherapy.

About Genentech in lung cancer

Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have five approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006484/en/

Contacts

Media Contact:
Nicolette Baker (650) 467-6800

Advocacy Contact:
Meg Harrison (617) 694-7060

Investor Contacts:
Loren Kalm (650) 225-3217
Bruno Eschli 011 41 61 687 5284

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting